RxDoctor Payments Data

Parker Pratt, OD

Optometrist · Fort Smith, ARNPI 1154807162

Payments from drug & device makers

$1,261in general payments, 2019–2025

Across 42 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$306
  • Glaukos Corporation$299
  • Biotissue Holdings Inc.$214
  • Oyster Point Pharma, Inc.$79
  • Johnson & Johnson Vision Care, Inc.$70
  • Johnson & Johnson Surgical Vision, Inc.$49
  • plus $245 from 11 others

What the payments were for

  • Food & beverage$1,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,261 in reported general payments places this provider in the 70th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$169,405
Medicare patients
1,022
Services billed
2,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$26,049
LumiganBimatoprost52$19,032
XiidraLifitegrast12$10,881
Cyclosporine25$8,123
VyzultaLatanoprostene Bunod17$7,254
CombiganBrimonidine Tartrate/Timolol14$6,868
Latanoprost591$3,706
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat189$2,157
ValacyclovirValacyclovir Hcl24$1,916
Prednisolone Acetate67$1,914
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$1,701
Doxycycline Hyclate67$1,472
Fluorometholone19$1,256
Timolol Maleate123$745
MoxifloxacinMoxifloxacin Hcl18$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$306$51,94995 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$22$18,13429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →